Core Insights - Tectonic Therapeutic, Inc. announced a late-breaking oral presentation at the ESC Heart Failure 2025 Congress, focusing on Phase 1b data for TX45, a long-acting relaxin therapy targeting Group 2 PH-HFpEF patients [1][2] Group 1: Company Overview - Tectonic Therapeutic is a clinical-stage biotechnology company specializing in the discovery and development of therapeutic proteins and antibodies that modulate GPCR activity [5] - The company utilizes its proprietary GEODe™ technology platform to develop biologic medicines aimed at addressing significant unmet medical needs [5] Group 2: Product Information - TX45 is an Fc-relaxin fusion protein designed to activate the RXFP1 receptor, exhibiting pharmacokinetics and biophysical properties that enhance its therapeutic potential [3] - Relaxin, the hormone targeted by TX45, functions as a pulmonary and systemic vasodilator with additional anti-fibrotic and anti-inflammatory properties [3] Group 3: Disease Focus - Tectonic is concentrating on Group 2 pulmonary hypertension, specifically PH-HFpEF, which arises from left-sided heart disease and leads to increased pulmonary artery pressure and right-sided heart failure [4] - Approximately one third to one half of the 1.4 million PH-HFpEF patients in the U.S. are affected by the more severe Combined pre- and post-capillary PH (CpcPH) [4]
Tectonic Therapeutic to Present Phase 1b Data for TX45 at European Society of Cardiology Heart Failure 2025